The first application of the V-SYNTHES2 synthon-based screening approach to the 173-billion-compound Enamine xREAL Space is reported, demonstrating near-linear computational scaling with only a 10–15% increase in cost relative to the 11-billion-compound REAL Space.
Abstract
Computational screening of giga-scale chemical spaces opens a cost-effective path to high-quality hit identification, providing entry points for drug discovery. As these on-demand spaces grow and successful applications multiply, rigorous blind benchmarks like CACHE Challenges provide important performance metrics for computational tools. Here, we report the first application of the V-SYNTHES2 synthon-based screening approach to the 173-billion-compound Enamine xREAL Space, a 16-fold expansion beyond its previous benchmarks, demonstrating near-linear computational scaling with only a 10–15% increase in cost relative to the 11-billion-compound REAL Space. We applied this workflow in CACHE Challenge #2, targeting the RNA-binding site of NSP13 (SARS-CoV-2), and CACHE Challenge #4, targeting the tyrosine kinase-binding domain of CBLB, both pockets lacking established pharmacology and representing extreme hit-finding challenges. Under blinded, independently validated conditions, V-SYNTHES2 ranked among the top-performing submissions: the 8% hit rate for NSP13 exceeded the field average of 2.3% and placed the approach among the top three workflows, while for CBLB, one compound meeting predefined hit criteria was identified. These results demonstrate that V-SYNTHES2 maintains robust performance at giga-scale on ligand-depleted targets, precisely the conditions where data-driven approaches would face fundamental limitations, and establish a quantitative performance baseline for synthon-based screening of hundred-billion-compound chemical spaces.
AdaptiveFlow enables drug discovery at unprecedented scale and supports the development of AI-driven methods, and identifies nanomolar inhibitors of two disease-relevant targets, ferroptosis suppressor protein 1 and poly(ADP-ribose) polymerase 1.
Domiziana Cecchini, AkshatKumar Nigam, Ming Tang et al.· Nature Biotechnology· 1 citation
MolDockLab addresses the challenge of structure-based virtual screening with an automated, data-driven framework that optimizes SBVS workflows for a protein target, balancing predictive performance and computational efficiency.
Hamza Agha, Y. Ibrahim, Michael Backenköhler et al.· npj Drug Discovery· 0 citations
MEL-Steered PharmacoNet is introduced, a parameter-efficient adaptation framework that specializes PharmacoNet to a given target through two composable mechanisms: empirical density-map steering of predicted pharmacophore hotspots and empirical fine-tuning of interaction-type scoring weights.
Wen-Jin Liu, Yong-Chan Hong, Thomas Ku et al.· bioRxiv· 0 citations
Real-SWIT, a generative ULVS framework that learns Enamine REAL Space as a synthesizable molecular distribution and couples this generator with a target-specific scoring model to enable docking-guided exploration of REAL Space at the level of complete molecule, establishes generative access to make-on-demand chemical s...
Kai-Yue Zhang, Ying Sun, Xin-Yue Li et al.· bioRxiv· 0 citations
Virtual screening remains a critical step in structure-based drug design, yet variability in docking algorithms and scoring functions often limits its reliability. To address this challenge, we introduce DockM8, an open-source platform for consensus virtual screening that integrates pocket detection, ligand preparation...
Antoine Lacour, Hamza Agha, Anna K. H. Hirsch et al.· Journal of Cheminformatics· 4 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.